Alerta

AGARWOOD OIL NANOEMULSIONS, METHODS PERTAINING TO AND USES THEREOF

Resumen de: AU2023447567A1

An oil-in-water nanoemulsion comprising a continuous aqueous phase, a surfactant, and a particulate oil phase, wherein the particulate oil phase is dispersed within the aqueous phase, wherein the particulate oil phase comprises particles comprising extracted agarwood oil having a diameter in the range of about and including 160 nm to about 200 nm.

POLYSIALIC ACID-POLYMER CONJUGATE AND NANOPARTICLE

Resumen de: AU2024252577A1

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

POLYION COMPLEX AND PHARMACEUTICAL COMPOSITION

Resumen de: WO2025243932A1

The present invention provides a polyion complex comprising: a block copolymer that has a hydrophilic polymer segment and a cationic poly(amino acid) segment; and a nucleic acid. The cationic poly(amino acid) segment includes an amino acid residue A that is selected from an amino acid residue having an achiral carbon atom as a carbon atom constituting the main chain and a polar non-charged amino acid residue, and also includes an amino acid residue B having a cationic group in a side chain.

ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B

Resumen de: EP4653462A2

Certain embodiments of the invention provide a method for treating a Hepatitis B virus infection and/or ameliorating one or more symptoms associated with a Hepatitis B virus infection in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an anti-PD-1 antibody, or fragment thereof.

CRYSTALLINE NANOPARTICLES COMPRISING ENZALUTAMIDE

Resumen de: AU2024209240A1

The invention relates to a composition comprising or essentially consisting of (i) nanoparticles comprising or essentially consisting of Enzalutamide in crystalline form and (ii) one or more physiologically acceptable polymers and/or copolymers. The invention also relates to processes for the preparation of such compositions, pharmaceutical dosage forms comprising or made from such compositions, and uses of such pharmaceutical dosage forms for medical purposes.

TARGETING OF ANTIGEN-PRESENTING CELLS BY NANOPARTICLES CONTAINING POLYOXAZOLINE-LIPID CONJUGATES

Resumen de: AU2023425729A1

A method of targeting antigen-presenting cells and delivering an encapsulated payload with lipid nanoparticles including a POZ-lipid conjugate. The encapsulated payload may include, but is not limited to, a nucleic acid payload such as mRNA or modified mRNA. These LNPs are not subject to accelerated blood clearance and they have a low or reduced immunogenicity profile in vivo.

CYCLOSPORINE NANOMOLECULAR AGGREGATE, EYE-DROP COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR

Resumen de: EP4652988A1

The present invention relates to a cyclosporine nanomolecular association and an eye-drop composition containing the same. More specifically, the present invention relates to a cyclosporine nanomolecular association and an eye-drop composition containing the same, which has excellent storage stability and can be delivered to target tissues (cornea and conjunctiva) more efficiently at lower concentrations compared to conventional formulations.

GEL LOADED WITH ALPHA-EMITTER RADIONUCLIDES

Resumen de: MX2025008266A

A mixture for treating a tumor, which includes an agent which turns into a hydrogel by addition of calcium ions, a vehicle carrying the agent in a manner allowing injection of the mixture into a tumor; and radium radionuclides bonded to the agent in a concentration sufficient to treat the tumor by radiotherapy.

COMPOSITIONS AND METHODS FOR TARGETING AND TREATING TUMOR

Resumen de: WO2024153122A1

Nanoparticles encapsulating core particles with attached photothermal agents, and therapeutic agents. The methods of imaging a tumor tissue and/or treating a subject suffering from tumor with the nanoparticles provided herein..

NANOASSEMBLIES FOR THE INTRACELLULAR DELIVERY OF ACTIVE PRINCIPLES OF AMINOACIDIC NATURE

Resumen de: EP4652991A1

The invention disclosed herein provides a delivery system for active molecules formed by nanoassemblies with a structure of a hybrid bilayer comprising an amphiphilic polymer, which may be functionalized with some moieties, and a phospholipid. This bilayer delimits an aqueous core in which an active molecule of aminoacidic nature has been incorporated. Furthermore, the nanoassemblies may incorporate a targeting moiety to direct the system to the target tissue. Moreover, the present invention also relates to a pharmaceutical composition comprising these nanoassemblies and to the therapeutic use of these nanoassemblies, as they are able to achieve an intracellular delivery and distribution of the active molecule into the target tissues.

COMPOSITIONS, METHODS, AND USES FOR POLYNUCLEOTIDE FORMULATIONS FOR DRYING AND PROLONGED STORAGE

Resumen de: WO2025029323A1

Embodiments of the present disclosure provide novel compositions and methods for making and using thermostable polynucleotide-containing formulations. In certain embodiments, compositions and methods are disclosed for creating thermostable polynucleotides and/or thermostable polynucleotides encoding at least one therapeutic agent for use in therapies for the treatment of health conditions in a subject. In some embodiments, compositions and methods are disclosed for creating thermostable polynucleotides for use in therapeutics, vaccines, and targeted gene therapies. In other embodiments, compositions and methods are disclosed for creating thermostable polynucleotides capable of being coated or encased for prolonged storage and/or timed-delivery.

LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES

Resumen de: CN120603809A

Disclosed are: a composition comprising a lipid-like compound; methods of making such compositions; and the use of these compositions in gene delivery applications.

THERAPEUTIC COMPOSITIONS AND METHODS

Resumen de: CN120603580A

Therapeutic compositions and methods. Disclosed is a composition comprising: a particle comprising hydrolysable doped silicon; one or more lipids; and an active pharmaceutical ingredient (API). Also disclosed are related products, methods and uses thereof.

THERAPEUTIC COMPOSITIONS AND METHODS

Resumen de: WO2024153954A1

Disclosed is a composition comprising: particles comprising one or more metals and hydrolysable silicon; one or more lipids; and an active pharmaceutical ingredient (API). Also disclosed are related products, methods and uses.

PHARMACEUTICAL FORMULATIONS OF GENE DELIVERY VEHICLES

Resumen de: CN120603600A

The present invention relates to formulations comprising miRNAs having improved stability for use in the treatment of diseases, including neurodegenerative diseases, such as spinal cerebellar ataxia type 3.5.

LIPID NANODISCS USEFUL IN SOLUBILISING MEMBRANE PROTEINS

Resumen de: CN120712078A

Provided herein is a composition comprising a lipid and a copolymer in the form of a nanodisk assembly. The copolymer comprises monomeric units of methacrylic acid and styrene. Also provided herein are aqueous solutions comprising the compositions of the invention, and methods of making the nanodisk assemblies. Further, provided herein are methods of solubilizing a hydrophobic component (e.g., a membrane protein) in an aqueous solution, comprising forming nanodisk assemblies of lipids, hydrophobic components, and copolymers of the invention.

RNA FORMULATIONS FOR PHARMACEUTICAL USE

Resumen de: CN120712350A

The present disclosure relates to an RNA comprising one or more miRNA binding sequences, wherein the one or more miRNA binding sequences bind to a miRNA present in a cell in which expression of the RNA is not desired. After administration, in particular after intramuscular or intravenous administration, the RNA is delivered to a cell such that the polypeptide encoded by the RNA is expressed in certain cells while inhibiting expression in other cells. In some embodiments, such cells comprise endothelial cells. The RNA compositions described herein allow for expression of a pharmaceutically active peptide or polypeptide in a subject by the RNA while reducing or avoiding the risk of undesirable effects caused by expression of the pharmaceutically active peptide or polypeptide in certain cells or tissues.

CYCLODEXTRIN-POLY (BETA AMINO ESTER) MACROMOLECULES FOR NANOPARTICLE DRUG DELIVERY

Resumen de: WO2024155885A1

Compositions that facilitate therapeutic delivery, as well as methods of making and using the same, are described herein. In particular, the composition including a cross-linked network of cyclic macromolecules and a plurality of functional groups, wherein the cyclic macromolecules are covalently cross-linked to one another by a plurality of cross-linking agents, and the plurality of functional groups are covalently associated with the cross-linked network of cyclic macromolecules, wherein the plurality of functional groups include (i) a proximal end covalently associated with the cross-linked network of cyclic macromolecules, and (ii) a distal end protruding out of the cross-linked network of cyclic macromolecules, wherein the distal end comprises a charge-imparting group.

Archexin的脂质体组合物

Resumen de: AU2024241934A1

Described herein are lipid nanoparticle (LNP) formulations for the delivery of active agents, including Archexin.

一种青光眼手术术中应用的毛蕊异黄酮苷PLGA水凝胶

Resumen de: CN121003583A

本发明公开了一种青光眼手术术中应用的毛蕊异黄酮苷PLGA水凝胶，涉及生物医药技术领域，按重量份计，包括如下组分制成：毛蕊异黄酮苷1~5份、PLGA 20~40份、乳化稳定剂0.1~3份、水凝胶基质3~8份、交联剂3~8份。本发明通过双重缓释体系的构建，释放持续时间长，可覆盖术后瘢痕增生高峰期；半固态凝胶形态贴合巩膜瓣，提升手术部位黏附性，可降低全身副作用和二次手术率；生物相容性优异，无明显毒性或刺激，并可规避传统抗代谢药物的并发症（如低眼压和炎症）。

用于鼻黏膜的mRNA疫苗递送纳米颗粒及其制备与应用

Resumen de: CN121003598A

本发明公开了一种用于鼻黏膜mRNA疫苗递送的纳米颗粒及其制备与应用，属于生物医药技术领域。所述纳米颗粒由季铵化壳聚糖、低分子量聚乙烯亚胺、醛基化聚乙二醇与mRNA通过自组装形成。QCS和PEI通过静电作用吸附mRNA，OPEG通过席夫碱键与PEI/QCS交联，形成pH响应型纳米颗粒。该颗粒在生理pH下稳定，保护mRNA免受降解；在内涵体酸性环境下解离，快速释放mRNA并促进内体逃逸。QCS赋予颗粒优异的黏膜黏附性和佐剂效应。本发明还提供了该颗粒的制备方法及在制备鼻黏膜mRNA疫苗中的应用。该疫苗能有效诱导黏膜sIgA和全身IgG/IgA应答，用于预防病毒性传染病和肿瘤。

一种载药聚合物纳米胶囊及其制备方法

Resumen de: CN121003596A

本发明提供了一种载药聚合物纳米胶囊及其制备方法。通过超分子自组装的方式，在亲疏水的作用下将难溶性药物负载在聚合物胶束中，在超分子静电引力和氢键等非共价作用力下，使带电单体富集在载药胶束的表面，再加入交联剂、引发剂在胶束表面引发原位自由基聚合反应，可以在不改变内部胶束的结构的前提条件下，在表面形成一层聚合物壳层，实现对内部疏水性药物的保护。经过修饰后的载药胶束在稳定性及细胞摄取方面展现出良好的性质，同时聚合物外壳可控释放药物，即外壳可以在特定条件下溶胀、降解，释放出内部负载的药物，在实验中展现出良好的效果，本发明解决了难溶性药物的稳定递送和可控释放。

一类单硅氧烷醚修饰的双羟基脂质分子及其应用

Resumen de: CN121005730A

本发明提供了一类单硅氧烷醚修饰的双羟基脂质分子、以及包含该脂质分子的纳米颗粒及其制备方法和应用。这一系列结构新颖的单硅氧烷醚修饰的双羟基可离子化的脂质分子制备方法具有合成简单、产率高的优点。同时，包含单硅氧烷醚修饰的双羟基可离子化脂质的LNP粒径均一且分散性好，对于核酸的包封率高，可以高效地递送核酸药物使其具有更好的进细胞效率、核酸的表达效率，溶酶体逃逸效率，并具有脾脏靶向性，在免疫治疗中具有重大的应用前景。

包含胰高血糖素样肽-1受体激动剂的新型药物组合物

Resumen de: AU2023392764A1

There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.

脂质颗粒

Nº publicación: CN121013730A 25/11/2025

Solicitante:

联合免疫股份有限公司

Resumen de: AU2024237452A1

To provide lipid particles that can be produced without relying on PEG-modified lipids, that are superior in medicinal effect, safety, or stability to lipid particles that rely on PEG-modified lipids, or that have different immunodynamics than lipid particles that rely on PEG-modified lipids.　Provided is a lipid particle, wherein the lipid particle contains an ionized lipid, a phospholipid, and a sterol as lipids constituting the lipid particle and contains a modified polysaccharide that includes a hydrophobic group.